24/7 Market News Snapshot 29 September, 2025 – NRX Pharmaceuticals, Inc. Common Stock (NASDAQ:NRXP)

September 29, 2025

DENVER, Colo., 29 September, 2025 (www.247marketnews.com) – (NASDAQ:NRXP) are discussed in this article.
NRX Pharmaceuticals, Inc. (NRXP) is experiencing noteworthy market activity as its stock opened at $3.03 and is currently trading at $3.28, representing an 11.19% increase from a previous close of $2.95. The trading volume has reached 770.15K shares, indicating robust investor interest, and the stock’s movement above both the opening price and prior close reflects a positive market sentiment. Traders are advised to keep an eye on crucial resistance levels above $3.28 and support around $3.00 for strategic decision-making.

In a significant development, NRX Pharmaceuticals has re-filed its Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for KETAFREE™, an innovative preservative-free intravenous (IV) ketamine formulation. This initiative responds effectively to the Department of Health and Human Services (HHS) priorities aimed at eliminating harmful preservatives from medications, while also addressing the critical shortage of ketamine that has affected the healthcare sector.

KETAFREE™ is designed to provide a safer alternative to traditional ketamine products, which often contain neurotoxic preservatives. This re-filing follows the FDA’s approval of NRx’s Suitability Petition regarding the proposed formulation. The global market for ketamine is anticipated to grow from approximately $750 million to $3.35 billion by 2034, signaling a significant rise in the demand for this vital medication.

Dr. Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals, expressed optimism about the company’s advancements, stating, “We appreciate the FDA’s swift response to our petition and look forward to bringing KETAFREE™ to market. This product represents both a commitment to patient safety and a substantial step towards restoring the production of essential drugs.”

With KETAFREE™ being manufactured in collaboration with Nephron Pharmaceuticals, NRx Pharmaceuticals is committed to pioneering advancements in therapies targeting central nervous system disorders, thereby addressing critical needs in patient care.

Related news for (NRXP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.